Oenostacin and its Analogue with Potent Antibacterial Activity.
Since the appearance of methicillin-resistant Staphylococcus aureus, empiric therapy for staphylococcal infections (particularly nosocomial sepsis) was changed to vancomycin in many health-care institutions. Presently, Vancomycin is the last line of control for the effective treatment of staphylococcal infections. However, increased use of vancomycin has led to the emergence of vancomycin resistant S. aureus (VRSA), which has considerable variance in estimates of its prevalence (0–1.3%–20%). Hence, the present technology is a strong step to address this problem as the pharmaceutically active analogue of Oenostacin elicits marked antibacterial activity against vancomycin sensitive and resistant Staphylococcus aureus and Staphylococcus epidermidis.
Sector: Biotechnology
Country: India
Area of Application: Pharmaceuticals, Healthcare
Keywords: Antibacterial, Vancomycin, Staphylococcus aureus
Advantages: 1. Potent antibacterial activity against S. epidermidis and S. aureus. 2. Minimum Inhibitory Concentration (MIC) value as 62.5µg/ml against S. epidermidis. 3. Active against Vancomycin drug resistant strain of S. aureus.
Environmental aspects:  
Development Status: Laboratory Model
Legal Protection: Patent
Technical specifications:  
Transfer Terms: Technology Licensing
Target Countries: World Wide
Estimated cost (US$):  
Upload any relevant document:  
Contact Person: BCIL
Address: Anuvrat Bhavan 5th floor, 210, Deen Dayal Upadhyay Marg, New Delhi
City: New Delhi
Country: India
Zip/Pin Code: 110002

Contact Technology Provider